AlphaLab Health

AlphaLab Health is a healthcare and life sciences accelerator that accelerates scientific, clinical, and market validation for early-stage healthcare and life science technology companies. It supports early-stage tech startups in their efforts to bring innovations to market, navigating key risk points of scientific, clinical, and commercial development.

Megan Shaw

Managing Director

21 past transactions

Resilient Lifescience

Pre Seed Round in 2023
Resilient Lifescience develops a wearable medical device to prevent opioid overdose deaths using naloxone.

D.Sole

Pre Seed Round in 2023
D.Sole specializes in the development of advanced foot insoles aimed at improving remote patient monitoring in podiatry, specifically for diabetic patients. These innovative, AI-powered insoles utilize multimodal sensors to detect early signs of complications, such as ulcers and nerve damage. By providing comprehensive physiological data, D.Sole enables clinicians to gain evidence-based insights for more effective foot treatments. The company's solution is notably more cost-effective than existing market options, detecting multiple foot complications compared to competitors that typically identify only one. This technology has the potential to significantly reduce healthcare costs, potentially saving hospitals over $100 million annually by decreasing readmission rates for foot complications, while private insurers could save more than $1 billion by minimizing expenses related to amputations and wound care.

Ilant Health

Pre Seed Round in 2023
Ilant Health specializes in obesity management and cardiometabolic healthcare services. The company focuses on delivering treatment for obesity and weight management, utilizing advanced analytics powered by unstructured machine learning. This technology generates significant insights that aim to lower overall healthcare costs and enhance return on investment for obesity treatments. By offering effective solutions for weight loss, Ilant Health enables clients to achieve better health outcomes while simultaneously reducing expenses and accessing health plans through value-based care.

Testa-Seat

Pre Seed Round in 2023
Testa-Seat specializes in developing affordable, adaptable seating solutions for children with special needs, utilizing tailored 3D printing technology. The company's products are designed to enhance mobility and independence for individuals with disabilities. Testa-Seat's body-contouring therapeutic seating provides optimal support for those with mild to moderate body control, helping to reduce the risks associated with improper seating during child development. By delivering its innovative seating devices to rehabilitation centers, hospitals, and private customers, Testa-Seat aims to improve comfort and wellness for disabled children and adults, positively impacting their mobility and overall quality of life for both individuals and their families.

Magnify Biosciences

Pre Seed Round in 2023
Magnify Biosciences provides a cutting-edge imaging platform as well as a comprehensive array of services to enable researchers, entrepreneurs, and diagnostic labs by giving unique insights into cellular architecture and molecular interactions.

Handl Health

Pre Seed Round in 2022
Operator of a SaaS-based healthcare price transparency platform intended to aggregate and contextualize price transparency, insurance, and demographic data. The company's platform offers health plans a simple way to comply with the CMS (Centers for Medicare and Medicaid Services) price transparency legislation while digitizing how patients shop, book, and pay for healthcare, enabling users to realize average cost savings to guide every healthcare purchasing decision.

InnSight Technology

Pre Seed Round in 2022
InnSight Technology is a biotechnology company focused on enhancing diagnostics and evaluation of eye diseases. The company develops innovative ophthalmic devices, including a novel hand-held biosensor designed for the detection of anterior ophthalmic injuries. Additionally, InnSight Technology works on advanced nanotechnology-based medical devices aimed at addressing specific clinical needs in ophthalmology. By providing these tools, the company seeks to improve ocular care for clinicians and their patients.

Advanced Optronics

Pre Seed Round in 2022
Advanced Optronics specializes in the design and manufacture of implantable sensors aimed at enhancing intraoperative monitoring during surgeries. These innovative sensors provide real-time feedback to surgeons, helping to minimize trauma and prevent damage to residual hearing during implant procedures. The company focuses on developing flexible and biocompatible sensor systems that facilitate less invasive surgical techniques across various medical applications. By integrating flexible micro-electromechanical system sensors with cochlear implants, Advanced Optronics aims to improve surgical outcomes and support surgeons in performing procedures with greater precision and care.

Naima Health

Seed Round in 2022
Naima Health is a healthcare technology company founded in 2018 and based in Pittsburgh, Pennsylvania. It specializes in developing health tools that utilize behavioral decision science and machine learning to enhance patient engagement in clinical care, particularly for pregnant women. The company's platform focuses on minimizing the risk of adverse pregnancy outcomes by offering a personalized and user-friendly pregnancy risk assessment and support tool. By combining individual-level input with statistical machine learning, Naima Health aims to empower at-risk women to better understand and communicate about their health risks, thereby facilitating access to necessary support and improving overall outcomes. The organization comprises a diverse team of researchers, scientists, and medical professionals committed to advancing maternal health.

Telling.ai

Seed Round in 2021
Telling.ai is a telehealth platform focused on assessing lung health through the analysis of voice and breath sounds. By capturing respiratory sounds in real-world settings, the company provides real-time feedback and optimizes data quality to support individuals with chronic lung conditions. Their technology identifies signatures in breath and speech that indicate various medical conditions, including respiratory diseases and infections. Telling.ai aims to assist in the management of care for over 1 billion people suffering from acute or chronic respiratory disorders, enabling timely interventions that can prevent costly hospitalizations and improve overall patient outcomes.

Parcel Health

Pre Seed Round in 2021
Parcel Health is dedicated to revolutionizing medication packaging by offering the world's first fully brandable and compostable paper-based prescription bottle. This innovative product aims to replace traditional plastic bottles, contributing to sustainability efforts and helping pharmacies and pharmaceutical companies achieve carbon neutrality goals. Parcel Health's packaging not only enhances the safety and integrity of medications during shipping but also improves logistical efficiency, minimizing in-transit damage and bolstering customer satisfaction. Designed to be child-resistant and elder-friendly, the company’s solutions improve pharmacy workflows and reduce medication errors, positioning Parcel Health as a leader in eco-friendly pharmaceutical packaging.

Hava Health

Seed Round in 2021
Hava Health, Inc. is a biotechnology company based in the United States that specializes in developing innovative solutions for nicotine addiction. The company manufactures a smoking cessation device that includes a connected vape pen designed to assist individuals in their efforts to quit smoking. This device pairs with a smartphone application called Hale, which serves as a digital support tool for users undergoing nicotine de-addiction. Through its focus on combining technology with therapeutic approaches, Hava Health aims to provide effective support for those seeking to overcome nicotine dependence.

MindTrace

Seed Round in 2021
MindTrace is a medical software company focused on enhancing neurosurgical procedures through the development of personalized 3D brain maps. By integrating advanced brain imaging with machine learning algorithms, the company creates simulations of surgical resection plans that allow neurosurgeons to predict patients' cognitive outcomes prior to surgery. This innovative approach enables surgeons to optimize the removal of brain tumors while minimizing damage to surrounding healthy tissue. Additionally, MindTrace's platform streamlines the process of analyzing brain imaging and behavioral data, reducing the time and effort required by medical teams. The company is supported by the Creative Destruction Lab, reflecting its commitment to advancing neurosurgical care.

Emergence Dental

Seed Round in 2021
Emergence Dental is a research and development medical device company established in 2019 and headquartered in Pittsburgh, USA. The company specializes in the design and pre-clinical development of innovative medical devices aimed at improving dental bone and soft tissue grafting procedures. Emergence Dental offers products made from metallic magnesium alloys, which safely resorb when implanted in the body. This technology enables oral surgeons and periodontists to reduce both the time and costs associated with dental bone grafting procedures for patients preparing to receive dental implants.

SpIntellx

Seed Round in 2021
SpIntellx, Inc. is a computational and systems pathology company based in Pittsburgh, Pennsylvania, specializing in spatial intelligence software products for cancer diagnosis. Established in 2017, the company offers innovative solutions such as SpIntellx, which analyzes image data sets from various imaging platforms and reagent types, enabling precise analysis of pathology tissue sections. Additionally, SpIntellx provides HistoMapr, a computational guide for pathologists, and TumorMapr, which examines the spatial interactions of biomarkers within whole slide images using multiplexed fluorescence. By leveraging unbiased spatial analytics powered by explainable AI, SpIntellx aims to enhance the understanding of complex cancer biology, contributing to advancements in medicine and research across drug development, diagnostics, and treatment pipelines.

JuneBrain

Seed Round in 2021
JuneBrain, LLC is a Washington, D.C.-based company founded in 2017 that focuses on developing wearable and non-invasive imaging devices for multiple sclerosis patients. The technology allows patients to monitor their disease activity from home, facilitating earlier detection of MS attacks and enhancing the monitoring of treatment efficacy. By leveraging telemedicine, JuneBrain aims to optimize remote assessment for neurological diseases, thereby enabling clinicians to track patients outside traditional clinical settings. The company's long-term vision includes extending its device's applications to a broader range of neurodegenerative diseases, promoting more accessible and frequent monitoring of brain health.

Gus Gear

Seed Round in 2021
Gus Gear specializes in the development and manufacturing of wearable securement clothing designed to protect implanted medical devices. The company's flagship product, the Central Line Vest, effectively prevents damage, breakage, and accidental removal of central catheters. By providing securement solutions for various medical devices, including ostomy pouches and feeding tubes, Gus Gear aims to enhance patient outcomes and quality of life. Their innovative approach enables patients to maintain a higher level of independence and well-being while undergoing medical treatment, allowing them to live their lives to the fullest despite any health challenges.

CytoAgents

Seed Round in 2021
CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.